Skip to main content
Equibles
TLPH logo

TLPH · Talphera, Inc. · Metrics

Track TLPH — free

Use TLPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TLPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.04 -0.02 (-1.43%) At close · Nov 12 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur operating losses and negative cash flows in the future. These conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$53.72M
Shares
51.91M
Volume · Nov 12 94.85K Avg daily vol (3M) 161.08K

TLPH metrics

76 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.04
Market cap
$53.72M

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
-1.9%
Price change (3M)
-25.0%
Price change (6M)
+16.7%
Price change (YTD)
-7.9%
Price change (1Y)
-18.6%
Trailing year
Price change (5Y)
—
52-week high
$1.47
52-week low
$0.72
Change from 52-week high
-28.6%
Change from 52-week low
+45.8%
Annualized volatility
71.4%
Annualized volatility (3M)
42.5%
Implied volatility (30D)
149.1%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.0
RSI (14D)
45.5
Price vs SMA 50
-6.2%
Price vs SMA 200
+3.6%
Avg volume (3M)
167,281
Relative volume
1.1
Average dollar volume
$196,672

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
51.91M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
54,501.1×
reciprocal yield 0.0%
P / book
3.8
reciprocal yield 26.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-27.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
17.5×
reciprocal yield 5.7%
EV / revenue historical average (5Y)
19.2×
reciprocal yield 5.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
—
Operating margin
-1,474,700.0%
Trailing 12 months
Net margin
-1,507,600.0%
Gross profit (TTM)
−$2.59M
Operating profit (TTM)
−$14.75M
Net income (TTM)
−$15.08M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$-0.35
Operating profit per diluted share (TTM)
$-3.25
EBITDA per diluted share (TTM)
$-3.06
Net income per diluted share (TTM)
$-1.48
Operating cash flow per diluted share (TTM)
$-1.36
Free cash flow per diluted share (TTM)
$-1.37
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.40
Stock compensation per diluted share (TTM)
$0.13
Book value per share
$0.35

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$1,000
Trailing 12 months
EPS growth YoY
-122.6%
Shares change YoY
+127.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-65.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-104.7%
Return on assets
-56.2%
Debt / equity
—
Current ratio
4.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$742,000
Total assets
$26.81M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.27M
Capital expenditures (TTM)
$0
R&D (TTM)
$6.70M
SG&A (TTM)
$8.04M
Stock compensation (TTM)
$794,000
R&D / revenue
670,400.0%
Stock compensation / revenue
79,400.0%

Ownership (13F)

9 metrics
13F filers
50
13F filer change QoQ
+5
Institutional ownership
46.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
30.6%
Private-fund adviser ownership
19.2%
Active holders' share change QoQ
+7.9%
Holder tenure
8.6
Price vs estimated holder cost
+31.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.0%

Short interest

3 metrics
Short interest
2.3%
Latest settlement · 27.7 days to cover
Days to cover
27.7d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1427925 CUSIP 00444T209 13F (30d) 34 filings 27 filers Visit website Investor relations